Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis

Dimitrios C Mastellos; Edimara S Reis; John D Lambris

doi:10.1016/j.ccell.2018.09.005

Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis

Cancer Cell. 2018 Oct 8;34(4):531-533. doi: 10.1016/j.ccell.2018.09.005.

Authors

Dimitrios C Mastellos¹, Edimara S Reis², John D Lambris³

Affiliations

¹ Division of Biodiagnostic Sciences and Technologies, INRASTES, National Center for Scientific Research "Demokritos," Aghia Paraskevi, Athens, Greece.
² Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA, USA.
³ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA, USA. Electronic address: lambris@pennmedicine.upenn.edu.

PMID: 30300576
DOI: 10.1016/j.ccell.2018.09.005

Abstract

In this issue of Cancer Cell, Medler et al. demonstrate that fibrinolytic enzyme-mediated generation of complement C5a reprograms tumor-infiltrating C5aR1⁺ macrophages into an immunosuppressive phenotype that dampens CD8⁺ T cell responses during squamous carcinogenesis. C5aR1 blockade combined with chemotherapy offers a promising immunomodulatory strategy for treating squamous cell carcinoma.

Publication types

Comment

MeSH terms

Carcinogenesis
Carcinoma, Squamous Cell*
Complement C5a*
Humans
Receptor, Anaphylatoxin C5a
T-Lymphocytes

Substances

Receptor, Anaphylatoxin C5a
Complement C5a